Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript Summary
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript Summary
The net loss increased by 25% in Q3 2024 to $2.6 million, primarily due to a change in the fair value of a warrant liability.The following is a summary of the Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript:
以下是vivos therapeutics, Inc. (VVOS) 2024年第三季度業績會的摘要：
Financial Performance:
財務表現：
Vivos Therapeutics reported a revenue of $3.9 million in Q3 2024, a 17% increase from Q3 2023.
Gross profit for Q3 2024 was $2.3 million, up 34% from the previous year, with a gross margin increase from 53% to 60%.
The net loss increased by 25% in Q3 2024 to $2.6 million, primarily due to a change in the fair value of a warrant liability.
Significant decrease in operating expenses and operating loss, contributing to improved financial health despite the increased net loss.
vivos therapeutics在2024年第三季度的營業收入爲390萬元，比2023年第三季度增長了17%。
2024年第三季度的毛利潤爲230萬元，比去年增長了34%，毛利率從53%提升到60%。
2024年第三季度的淨虧損增加了25%，達到260萬元，主要由於擔保負債公允價值的變化。
營業費用和營業虧損顯著減少，從而改善了財務健康狀況，儘管淨虧損有所增加。
Business Progress:
業務進展：
Vivos Therapeutics has shifted its marketing and distribution focus, moving away from enrolling VIPs to affiliating with sleep providers, indicating a strategic shift in business operations.
The strategic alliance rollout with Rivas Health marked the first implementation of the new model, expected to scale up in Q4 2024 and through 2025, potentially increasing access to Vivos products for OSA patients.
The company also highlighted its recent FDA clearances for treating OSA in both children and adults, which is expected to broaden market opportunities and enhance product credibility.
vivos therapeutics已經改變了其市場營銷和分銷策略，從招募VIP轉向與睡眠提供者建立合作，表明在業務運營上的戰略轉變。
與Rivas Health的戰略聯盟實施標誌着新模型的首次實施，預計將在2024年第四季度及2025年擴展，可能會增加OSA患者對vivos therapeutics產品的獲取。
公司還強調其最近獲得FDA批准的針對兒童和成人OSA的治療，這預計將拓寬市場機會並增強產品可信度。
Opportunities:
機會：
The strategic shift towards focusing on sleep provider affiliations over VIP enrollments is expected to broaden the patient base and enhance revenue streams. This is also supported by having achieved significant FDA clearances.
Given the high prevalence of sleep apnea and the low penetration of effective treatments, the strategic alignment with sleep clinics could address large untapped markets.
向專注於睡眠提供者合作關係的戰略轉變預計將擴大患者基礎並增強營業收入來源。這也得到了顯著獲得FDA批准的支持。
考慮到睡眠呼吸暫停的高發病率和有效治療的低滲透率，與睡眠診所的戰略對接可能會解決大量尚未開發的市場。
Risks:
風險：
Transitioning to a new sales and distribution model could face execution risks given the reliance on the successful scaling of strategic alliances. The lack of immediate revenue replacement as the company transitions from VIP enrollments might affect short-term financial stability.
過渡到新的銷售和分銷模型可能面臨執行風險，因爲它依賴於戰略聯盟成功擴大規模。在公司從VIP註冊過渡的過程中，缺乏即時營業收入的替代可能會影響短期財務穩定性。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
